KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022)

Historic Accumulated Depreciation for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2022 value amounting to $18.5 million.

  • AbCellera Biologics' Accumulated Depreciation rose 8802.16% to $18.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.5 million, marking a year-over-year increase of 8802.16%. This contributed to the annual value of $18.5 million for FY2022, which is 8802.16% up from last year.
  • According to the latest figures from Q4 2022, AbCellera Biologics' Accumulated Depreciation is $18.5 million, which was up 8802.16% from $15.7 million recorded in Q3 2022.
  • In the past 5 years, AbCellera Biologics' Accumulated Depreciation ranged from a high of $18.5 million in Q4 2022 and a low of $5.6 million during Q4 2020
  • In the last 3 years, AbCellera Biologics' Accumulated Depreciation had a median value of $9.8 million in 2021 and averaged $10.7 million.
  • As far as peak fluctuations go, AbCellera Biologics' Accumulated Depreciation soared by 7590.4% in 2021, and later surged by 8802.16% in 2022.
  • Quarter analysis of 3 years shows AbCellera Biologics' Accumulated Depreciation stood at $5.6 million in 2020, then soared by 75.9% to $9.8 million in 2021, then surged by 88.02% to $18.5 million in 2022.
  • Its Accumulated Depreciation stands at $18.5 million for Q4 2022, versus $15.7 million for Q3 2022 and $13.2 million for Q2 2022.